Regeneron agreed to partner with Telix Pharmaceuticals to co-develop and co-commercialize multiple radiopharmaceutical programs, marking Regeneron’s entry into radiopharmaceuticals. Under the deal’s 50/50 cost-and-profit-sharing structure, Telix will receive AU$57 million (US$40 million) upfront for four initial programs based on Regeneron’s antibody portfolio. Regeneron also has options to add four more programs, positioning the collaboration as a multi-target effort across solid tumors. The partnership extends biopharma deal momentum toward radiopharma platforms where antibody targeting and isotope payloads can align with tumor-directed delivery.